🌍 PulseCath is expanding their global footprint
Exciting news! Another milestone reached. We are proud to announce the achievement of product registration for…
Jincy George
Clinical & Sales Support Manager
We have a mission!
PulseCath® is focused on developing ground-breaking technologies designed to assist the life sustaining pumping functions of the failing heart.
SEE OUR
Facts & Figures
Registrations
> 45 countries approved registrations
Cases
> 100 shared cases on LinkedIn; > 200 reported cases
> 1.000 iVAC 2L sold
> 35 distributor agreements
Hospitals
> 35 hospitals use iVAC 2L on a regular base; > 7 Centers of Excellence.
Patients
> 400 patients world wide treated by iVAC 2L
Clinical evidence
> 30 publications
Indication
The iVAC 2L is intended for use in patients with impaired left ventricular function which require left ventricular mechanical circulatory support for up to 24 hours
First 2 iVAC 2L cases in a new center in Romania
After first successful cases in Romania, performed at “Niculae Stancioiu” Heart Institute in Cluj-Napoca, yesterday, at…
PulseCath expands in Asia-Pacific (APAC) region
In Indonesia the first successful iVAC 2L case was performed by Prof. Taguh Santoso in Medisra…
MEET OUR
Medical advisors
Clinical programme supported by leading cardiologists